Skip to main content
. Author manuscript; available in PMC: 2014 Jun 4.
Published in final edited form as: Phys Biol. 2013 Jun 4;10(3):035002. doi: 10.1088/1478-3975/10/3/035002

Figure 4. Cycloheximide reduces mean death time and variability in death times, and proteasome inhibition partially reverses this process.

Figure 4

(a) Dose-response curves of HeLa cells treated with increasing doses of TRAIL +/− increasing doses of CHX for 4h, monitored for cell death by flow cytometry using an antibody that recognizes cleaved PARP. (b) Time of death distributions and percentage of surviving cells for HeLa cells treated with TRAIL (50ng/ml; yellow), TRAIL + CHX (2.5μg/ml; blue), or TRAIL + CHX + MG-132 (10μM; red) for 16h and imaged by live-cell microscopy. Percent cells surviving at the end of the movie is plotted to the right of the dotted line. Shown is a representative of three independent experiments that yielded similar results. (c) Quantitation of the spread of the death times for cells pre-treated with CHX for 2h prior to treatment with TRAIL + CHX, compared to co-treatment with TRAIL + CHX or treatment with TRAIL alone. (d) Quantitation of the spread of the death times in (b). Median, IQR, and range of death times for each treatment appear in the box and whisker plots as described for Figure 3. 50-100 cells were analyzed per condition.